Evidence map›Paper›PMID 25320680›Full record

ArticlePeerJ2014

Synthesis and anti-tubercular activity of 3-substituted benzo[b]thiophene-1,1-dioxides.

N Susantha Chandrasekera, Mai A Bailey, Megan Files, Torey Alling, Stephanie K Florio, Juliane Ollinger, Joshua O Odingo, Tanya Parish

Abstract read
In one paragraph

Article in PeerJ, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. An Overview of the Pharmacological Activities and Synthesis of Benzothiophene Derivatives.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024
    Review
  3. Synthesis and Evaluation of 3-Halobenzo[Pharmaceuticals (Basel, Switzerland) · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

N Susantha ChandrasekeraTB Discovery Research, Infectious Disease Research Institute , Seattle, WA , USA.
Mai A BaileyTB Discovery Research, Infectious Disease Research Institute , Seattle, WA , USA.
Megan FilesTB Discovery Research, Infectious Disease Research Institute , Seattle, WA , USA.
Torey AllingTB Discovery Research, Infectious Disease Research Institute , Seattle, WA , USA.
Stephanie K FlorioTB Discovery Research, Infectious Disease Research Institute , Seattle, WA , USA.
Juliane OllingerTB Discovery Research, Infectious Disease Research Institute , Seattle, WA , USA.
Joshua O OdingoTB Discovery Research, Infectious Disease Research Institute , Seattle, WA , USA.
Tanya ParishTB Discovery Research, Infectious Disease Research Institute , Seattle, WA , USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We demonstrated that the 3-substituted benzothiophene-1,1-dioxide class of compounds are effective inhibitors of Mycobacterium tuberculosis growth under aerobic conditions. We examined substitution at the C-3 position of the benzothiophene-1,1-dioxide series systematically to delineate structure-activity relationships influencing potency and cytotoxicity. Compounds were tested for inhibitory activity against virulent M. tuberculosis and eukaryotic cells. The tetrazole substituent was most potent, with a minimum inhibitory concentration (MIC) of 2.6 µM. However, cytotoxicity was noted with even more potency (Vero cell TC50 = 0.1 µM). Oxadiazoles had good anti-tubercular activity (MICs of 3-8 µM), but imidazoles, thiadiazoles and thiazoles had little activity. Cytotoxicity did not track with anti-tubercular activity, suggesting different targets or mode of action between bacterial and eukaryotic cells. However, we were unable to derive analogs without cytotoxicity; all compounds synthesized were cytotoxic (TC50 of 0.1-5 µM). We conclude that cytotoxicity is a liability in this series precluding it from further development. However, the series has potent anti-tubercular activity and future efforts towards identifying the mode of action could result in the identification of novel drug targets.

Indexed as

AntibacterialAntimicrobialBenzothiophene dioxideDrug discoveryHigh throughput screeningMycobacterium tuberculosisTuberculosis

Identifiers

PMID25320680
PMCPMC4193402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.